checkAd
    Legend Biotech Corporation Aktie
    40,20
     
    EUR
    +5,79 %
    +2,20 EUR
    Letzter Kurs 05.06.24 Tradegate
    39,60
     
    EUR
    76 STK
    Geldkurs 10:00:12
    40,40
     
    EUR
    100 STK
    Briefkurs 10:00:12
    ISIN: US52490G1022 · WKN: A2P5AH · SYM: 9LB · Kaiman-Inseln

    Neueste Nachrichten

    Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
    03.06.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Participate in the Jefferies Global Healthcare Conference
    29.05.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
    23.05.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
    13.05.24 · Business Wire (engl.) · Legend Biotech Corporation
    CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    22.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
    11.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech’s CARVYKTI (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
    06.04.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
    19.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    CARVYKTI (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
    15.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 11.03.2024
    11.03.24 · wO Chartvergleich · DMG MORI
    Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
    11.03.24 · Business Wire (engl.) · Legend Biotech Corporation
    Legend Biotech Announces Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
    23.02.24 · Business Wire (engl.) · Legend Biotech Corporation